Related Experiment Video
Updated: Jan 12, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Efficacy of Immunotherapy in Treating Metastatic Melanoma: A Randomized Controlled Trial
Maariyah Arsheen1, Madhavi Khokhar2, Vikesh Kumar R Shah3
1MBBS Graduate, Ayaan Institute of Medical Sciences, Teaching Hospital and Research Centre, Telangana, India.
Introduction:
Immunotherapy has revolutionized the treatment of metastatic melanoma, offering prolonged survival and improved outcomes. Checkpoint inhibitors like PD-1/PD-L1 have demonstrated significant efficacy in modulating the immune system's response to tumors. This randomized controlled trial aims to evaluate the efficacy of these therapies compared to standard care.
Methods:
A randomized trial was conducted on patients with advanced metastatic melanoma, who were assigned to either immunotherapy or traditional chemotherapy. Parameters included progression-free survival (PFS), overall survival (OS), and immune-related adverse events. Data analysis was conducted using appropriate statistical tests, with P values set at < 0.05 for significance.
Results:
Immunotherapy significantly improved PFS and OS compared to chemotherapy (P < 0.01). Adverse events were manageable and consistent with the known profiles of checkpoint inhibitors.
Conclusion:
Immunotherapy provides a superior therapeutic option for patients with metastatic melanoma, offering improved survival outcomes with manageable toxicity. Further research is needed to refine patient selection and optimize treatment combinations.
